Novo faces new hurdle in long-acting insulin race
05:33 EDT 18 Jul 2012 | Reuters
COPENHAGEN (Reuters) - Novo Nordisk's bid to challenge Sanofi's dominance of the long-lasting insulin market hit another snag after U.S. regulators delayed approval of the Danish drugmaker's degludec until after an expert review.
Original Article: Novo faces new hurdle in long-acting insulin race
More From BioPortfolio on "Novo faces new hurdle in long-acting insulin race"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
